Third-party consensus forecasts and institutional analyst 12-month price targets for BioNTech SE (NASDAQ: BNTX) generally range between $110 and $140 per share, with variations depending on upcoming clinical trial data readouts, regulatory milestones for oncology therapeutics, and broader biotechnology sector valuation trends.